Total amount: € 0,00
HOW TO ORDER
A Journal on Heart and Vascular Diseases
Official Journal of the Italian Society of Angiology and Vascular Pathology
Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,752
Minerva Cardioangiologica 2007 June;55(3):317-23
Is dobutamine stress echocardiography predictive of middle and late term outcomes in mitral stenosis patients?
Chirio C., Anselmino M., Mangiardi L., Morello M., Oliaro E., Omedè P., Trevi G. P.
Department of Cardiology University of Turin Turin, Italy
Aim. In mitral stenosis (MS) patients with a poor symptom-echocardiography correlation, dobutamine stress echocardiography (DSE) still does not have a confirmed utility and predictive value. Our aim is to evaluate usefulness of DSE in assessing 2 and 5 years clinical outcomes.
Methods. Forty-four consecutive patients with known MS were submitted, between April 1998 and July 1999, to basal and DSE. Patients were divided in 2 groups: group A if during DSE was reached a mean mitral gradient (MG) ≥15 mmHg and/or a pulmonary arterial pressure (PAP) ≥60 mmHg, and group B if MG and/or PAP were respectively lower than 15 and 60 mmHg. Endpoints considered were death, hospitalization for acute pulmonary edema, complications associated with mitral valve disease and mitral valve interventions (percutaneous or surgical). Mean follow-up was 73.6±16.6 months.
Results. Mean age was 55.2±10.5 years; 83.7% were women; NYHA class was I-II-III respectively in 18.6%, 58.1% and 23.3% of the patients; mean mitral valve area was 1.39±0.26 cm2; mean MG 8.05±2.54 mmHg; PAP 39.3±7.9 mmHg. Twenty-five patients met criteria for group A and 18 for group B. The event-free interval (27.9±32.1 months in group A vs 53.5±25.8 months in group B; P=0.008) and the 2 years event-free survival (40% for group A vs 88.9% for group B; P=0.002) showed significantly different patterns between the 2 groups. The 5 years survival analysis did not reach significancy.
Conclusion. DSE seems to detect MS patients that will have rapid evolution of their valvular disease within 24 months.